Q-omics provides the consensus-scored TCF7L1 profile across patient tissues and cancer cell-line models. TCF7L1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TCF7L1 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, TCF7L1 RNA expression shows 19,066 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where TCF7L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCF7L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCF7L1 survival associations across molecular data types. TCF7L1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCF7L1 RNA expression–survival associations across cancer types. High TCF7L1 expression shows unfavorable associations in BLCA, MESO, COAD, STAD and KIRP, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TCF7L1 RNA expression.
This table summarizes TCF7L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TCF7L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCF7L1 shows lower tumor expression in THCA, KICH, KIRP, COAD and BLCA and higher tumor expression in HNSC. The THCA box plot shows higher TCF7L1 RNA expression in normal versus tumor tissue (log2 FC = −3.021, t-test p < 0.001).
This table shows molecular features associated with TCF7L1 in patient tissues and cancer cell lines. In patient samples, TCF7L1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TCF7L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
